Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP. Ferguson ID, et al. Among authors: shah n. Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6. Nat Commun. 2022. PMID: 35840578 Free PMC article.
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Ghobrial I, et al. Among authors: shah n. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31023594 Review.
CAR T-cell therapy: is it prime time in myeloma?
Sidana S, Shah N. Sidana S, et al. Among authors: shah n. Blood Adv. 2019 Nov 12;3(21):3473-3480. doi: 10.1182/bloodadvances.2019000370. Blood Adv. 2019. PMID: 31714964 Free PMC article. Review.
CAR T-cell therapy: is it prime time in myeloma?
Sidana S, Shah N. Sidana S, et al. Among authors: shah n. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):260-265. doi: 10.1182/hematology.2019000370. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808895 Free PMC article. Review.
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG 3rd, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Huang HH, et al. Among authors: shah n. Nat Commun. 2020 Apr 22;11(1):1931. doi: 10.1038/s41467-020-15521-4. Nat Commun. 2020. PMID: 32321912 Free PMC article.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: shah n. Blood Adv. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. Blood Adv. 2020. PMID: 32433744 Free PMC article.
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. Ramkumar P, et al. Among authors: shah n. Blood Adv. 2020 Jul 14;4(13):2899-2911. doi: 10.1182/bloodadvances.2019001346. Blood Adv. 2020. PMID: 32589729 Free PMC article.
8,630 results